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3 
Introduction 
Weight loss and muscle loss are common in people living with cancer, with up to 50% 
experiencing involuntary weight loss at any time point in their cancer journey (1), and between 
11 and 74% having sarcopenia or significant muscle loss (2,3). These changes in body 
composition have been related to poor outcomes, such as increased treatment toxicity, 
impaired quality of life and reduced survival duration (4,5). Poor outcomes are not restricted to 
those who are underweight with severe weight loss; sarcopenia alone has been  shown to be a 
prognostic marker across all BMI categories, ranging from underweight to obesity (5).  
Several mechanisms behind weight loss and muscle wasting in cancer have been 
identified, such as systemic inflammation, tumour-induced metabolic alterations, inadequate 
dietary protein intakes and physical activity levels, poly-pharmacy, or a combination of these 
(6,7). We recently showed that a higher protein turnover and muscle protein breakdown in 
people with cancer was evident when compared in matched healthy controls, and that protein 
turnover and muscle breakdown were associated with muscle weakness and impaired physical 
function (8). 
So far, the main nutritional strategy to prevent or treat muscle wasting in people with 
cancer has been the adequate provision of dietary energy and substrates, such as 
macronutrients, mainly protein. Amino acids from protein are known to be required for muscle 
protein synthesis. Several studies in humans show that 20 to 35 g of a high quality protein is 
required to reach a maximal muscle protein synthesis (9,10). Higher amounts, i.e. 70 g of 
dietary protein intake, result in greater reduction in whole body protein breakdown than a 40 g 
dietary protein intake, and this will positively affect protein anabolism (10).  
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To achieve this, the main strategy to optimise dietary intake is nutritional counseling, 
with or without the provision of oral nutritional supplements (ONS), enteral nutrition or 
parenteral nutrition. However, despite the positive results of these strategies on dietary intake 
and body weight, results on muscle mass, quality of life and clinical outcomes are not 
convincing. A recent meta-analysis indicated an overall benefit of ONS on body weight during 
chemo(radio)therapy, and ONS enriched with n-3 PUFA showed attenuation of lean body mass 
loss and improvement of some quality of life domains, but no conclusions could be drawn on 
treatment toxicity or survival (11). Moreover, in advanced stages of cancer, people could 
become ‘refractory cachectic’ meaning that nutrition interventions are not effective due to 
progressive disease and cachexia (12). By using stable isotope technologies in an acute study 
design (5 hours), Deutz et al showed that a high-leucine ONS containing omega-3 PUFAs and 
HMB in people with advanced cancer was significantly more effective in stimulating muscle 
protein synthesis, whereas a conventional ONS did not change muscle protein synthesis (13). 
Engelen et al showed that an anabolic response was reached after oral intake of 14 g of 
essential amino acids and leucine caused an anabolic response in people with advanced lung 
cancer (14). Other studies have shown potential benefits of HMB and essential amino acid 
mixtures in malnourished older adults (15) and in hospitalised older adults with chronic 
obstructive pulmonary disease (COPD), chronic heart failure (CHF), acute myocardial infarction 
or pneumonia (16).  
To understand the mechanism of nutrition interventions in cancer and to develop 
effective future interventions, it is necessary to look at the acute effects of feeding on the 
response of the body and the ability to reach an anabolic response. This paper will explore and 
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summarise the emerging evidence on metabolic effects of acute oral interventions on whole 
body protein kinetics and muscle protein synthesis in people with cancer.  
   
The role of acute oral feeding in cancer 
This narrative review focuses on the effects of acute (<24 hours) oral feeding on protein 
metabolism in cancer. Protein metabolism includes, among others, muscle protein synthesis, 
muscle protein breakdown and the anabolic response to feeding. Kim et al defined the anabolic 
response as “the difference between protein synthesis and protein breakdown, or the net 
protein balance, in response to ingestion of protein or a meal containing protein. It usually 
refers to gain of muscle protein but can involve the entire body” (10).  
Muscle protein balance in the human body is controlled by many signalling pathways, 
including an anabolic arm reliant on growth factors and nutrient signalling via (among others) 
the mTOR pathway. The catabolic arm involves signalling cascades connected to autophagy 
genes and ubiquitin-mediated proteasomal degradation of myofibrils (17). Within the anabolic 
arm, the right amount and type of amino acids from dietary protein are required to achieve 
muscle protein synthesis. It is well known that oral amino acids stimulate skeletal muscle 
anabolism in healthy individuals (10), as well as in people with diseases such as COPD (18) and 
cancer (14). There are age-related differences in the anabolic response, with the elderly 
needing more amino acids than young adults to reach a comparable anabolic response, and in 
sick people there could be a higher breakdown, lower protein synthesis, or both, impacting on 
the net protein balance and anabolic response to protein (9).  
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Acute metabolic response to oral feeding 
A handful of metabolic studies have investigated the effects of acute oral feeding in people with 
cancer, utilising oral amino acids, oral nutritional supplements or meals (see Table 1).  
One of the first studies investigating the effects of oral amino acids on muscle protein 
anabolism in cancer was conducted by Dillon et al (19). In 6 women with ovarian cancer 
receiving chemotherapy, who showed evidence of systemic inflammation and weight loss, 18 
oral boluses of 2.22 g amino acids (in total 40 g of amino acids, of which 18 g essential amino 
acids) significantly decreased protein breakdown, which resulted in an improved net muscle 
protein synthesis. Engelen et al investigated the metabolic effects of two amino acid mixtures in 
lung cancer (14). In 13 people with NSCLC with systemic inflammation, and critical weight loss 
in 38% of the group, 14 g of a free EAA mixture induced a higher protein synthesis and net 
protein anabolism than a regular whey protein mixture of EAA and non-EAA. Interestingly, 
leucine from the free EAA mixture did not contribute to the anabolic response. There was a 
positive correlation between net protein anabolism and the amount of EAA consumed, as well 
as the EAA appearance in the systemic circulation. This correlation was independent of weight 
loss, systemic inflammatory response or length of survival.  
 Standardised drinks containing protein, fat and carbohydrates,  also known as ONS are 
often prescribed to enrich the diet of people with cancer. Several studies applied ONS in 
metabolic studies in people with cancer. Early work from Barber et al looked at albumin and 
fibrinogen synthesis rates in people with pancreatic cancer and healthy controls (n=8, n=6 
respectively), and showed that in both groups, protein synthesis rates were upregulated during 
consumption of  hourly sips of an ONS for 4 h (20). In a mixed group of people with cancer, the 
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use of ONS high in EAA and omega-3 PUFAs was shown  to increase muscle protein build-up 
significantly better than conventional supplements (13).  
In a small group of people with pancreatic cancer and signs of cachexia, sips of ONS 
were consumed over 4 h. In this study, net protein synthesis in response to the sip feeding was 
similar in cancer and healthy subjects, however, in pancreatic cancer only protein breakdown 
was decreased, whereas in healthy controls protein synthesis was stimulated and breakdown 
decreased (21). In a cohort of women with stage II breast cancer, protein synthesis was 
assessed prior to and within 24 h after mastectomy surgery. Surgery was shown to upregulate 
fasted protein synthesis and breakdown rates, and reduce net protein catabolism (22).  
We retrieved two studies from the 1980-90s that investigated short term effects of 
meals or standardised diets on anabolic response. One study applied identical food intake for 2 
days, both preoperatively and postoperatively in colorectal cancer: ad libitum on the first day 
and 6 equal portions every 2 h during the experimental period (23). No significant differences in 
rates of nitrogen flux, protein synthesis and protein breakdown were found before and after 
tumour resection. Both before and after tumour resection, nitrogen balance was positive with 
levels varying between +0.98 and +2.55 g/24 h. The investigators estimated that 1g N / 24 h is 
required for 1 kg of lean mass buildup in 1 month.  
In non-cachectic people with non-metastatic lung cancer, compared with controls 
undergoing elective aneurysm surgery, whole body protein turnover and leucine oxidation were 
assessed during 4 h postabsorptive and 4 h of feeding. Four small hourly meals composed of 
bread, margarine, cheese, raisins, and milk were consumed by subjects. During feeding, leucine 
oxidation and incorporation into protein remained the same and release of leucine caused by 
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protein breakdown dropped. Despite higher incorporation and release of leucine in cancer than 
in controls, the protein balance was not improved (24).  
Lastly, in a group of 5 people, of which 4 had lung and 1 had kidney cancer, hourly meals 
of a milk based liquid diet were administered over 10 hours as well as IV isotopes of leucine and 
sodium bicarbonate. Despite a comparable whole body protein synthesis and breakdown in 
cancer subjects and healthy controls, muscle samples showed a significantly lower muscle 
protein synthesis in those with cancer than in healthy controls (25).  
Although the above studies are small and heterogenous, all but one study showed that 
people with cancer are able to achieve protein anabolism in response to a high protein meal or 
supplement.  
 
Potential nutrients for future research 
The next paragraph describes other nutrients that could have anabolic effects in cancer. The 
basic chemical properties and mechanism of action of the nutrients are summarised in Table 2.  
 
Branched-chain amino acids 
Branched-chain amino acids (BCAA) are a group of EAA with a similar lateral radical chain. They 
are transaminated in skeletal muscle during exercise, generating acetyl-CoA to the Krebs Cycle 
and assisting with muscle recovery from exercise. Branched-chain amino acids also activate the 
mammalian target of rapamycin (mTOR) pathway when glutamine is lacking (e.g. in cancer), 
and thus reduce protein breakdown and stimulate protein synthesis in cancer (26). There are 
three branched-chain amino acids (BCAA): leucine, isoleucine and valine. Leucine has been 
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studied most extensively regarding its effects on muscle protein synthesis via initiation of 
signal-transduction pathways (27,28). Leucine is also a source of HMB (see next paragraph).  
In mouse cancer cachexia models, a leucine-enriched oral diet resulted in greater 
maintenance of lean muscle mass compared with a standard diet (29,30). Some human studies 
demonstrated beneficial effects of administration of total parenteral nutrition supplemented 
with BCAA on muscle protein metabolism by inhibiting protein breakdown and promoting 
protein synthesis and leucine balance (31,32).  
One double blinded RCT by Cangiano et al applied oral BCAA and placebo mixtures for 7 
days in people with resectable cancers. This study showed marked improvements in metabolic 
parameters (decreased free tryptophan/LNAA ratio decreased in BCAA group), reduced 
incidence of anorexia, and increased energy intake. Effects on protein metabolism were not 
assessed (33).  
Therefore, leucine and a mixture of BCAA administered orally or by parenteral nutrition 
showed to have beneficial effects on protein synthesis and other cachexia parameters (e.g. 
anorexia, dietary intake) in a small number of animal and human studies. More research is 
needed to test short- and long term effects of BCAA on muscle protein synthesis in people with 
cancer.  
 
ß-hydroxy-ß-methylbutyrate (HMB) 
HMB is a metabolite of leucine and has an inhibitory effect on protein breakdown via a number 
of mechanisms (34,35). HMB suppresses the ubiquitin-proteasome proteolytic pathway, up-
regulates protein synthesis via the mTOR pathway, and stabilizes cell membranes via the rate 
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limiting enzyme to cholesterol synthesis HMG- coenzyme A reductase (34). It can also decrease 
cell apoptosis, thus improving cell survival; and increase proliferation and differentiation of 
muscle stem cells, via the MAPK/ERK and PI3K/Akt pathways (35). HMB directly enhances 
muscle protein synthesis and mitochondrial dynamics in skeletal muscle via several metabolic 
pathways (36,37). A few studies have shown increases in lean mass, muscle strength and 
physical performance after adding HMB to a high protein ONS in geriatric (15,38,39), 
perioperative and rehabilitation settings (35). From these heterogeneous studies, no solid 
conclusions can be drawn and the impact of HMB on muscle maintenance or buildup and 
clinical outcomes needs to be confirmed yet.  
In humans with cancer, 3 studies have investigated the effect of HMB, supplemented as 
part of an amino acid mixture. One study applied  a daily dose of 3 g HMB/14 g arginine/14 g 
glutamine supplement vs. an isonitrogenous mix of NEAAs for 24 weeks in an RCT including 32 
weight-losing subjects with cancer. The intervention group gained 1.12 kg of fat free mass, the 
control group lost 1.34 kg of weight on average, and the intervention group maintained their 
fat free mass at 24 weeks (intervention: +2.27 kg vs. controls: +0.27 kg) (40). A large RCT was 
conducted in 472 weight-losing subjects with advanced cancer, applying 
HMB/arginine/glutamine for 8 weeks. The intervention group showed a trend toward higher 
lean mass, statistical significance was not reached. In this study, only 37% of participants 
completed the study, which could have impacted on the results (41). Perioperative nutritional 
support with HMB, arginine, and glutamine (1.2 g HMB, 7 g L-Arg, and 7 g L-Gln) or placebo 
(isocaloric juice) in 60 subjects undergoing surgery for abdominal malignancies. Supplements 
were provided once daily for 3 days preoperatively and once daily for 7 days postoperatively 
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and the primary outcome of this study was incidence of wound complications. No significant 
differences were found in body composition or handgrip strength. Serum growth hormone (GH) 
levels were significantly higher for subjects whose total intake was > 80% of planned volume in 
the HMB/Arg/Gln group (42).  
With regards to HMB supplementation in humans, there are insufficient studies to draw 
any conclusions on the effects of HMB on protein metabolism in cancer. 
 
Creatine 
Creatine (N-aminoiminomethyl-N-methylglycine) is produced in the body from glycine and 
arginine, requiring methionine to catalyze the transformation to creatine. It plays an essential 
role in rapid energy provision during skeletal muscle contraction (43) and is endogenously 
synthesized or ingested from the diet. It has been shown to impair energy metabolism and 
reduce tumour growth in animals. A 70 kg person has a creatine pool of 120 g and produces 2 g 
per day from dietary and endogenous sources. Supplementation of creatine temporarily 
reduces the normal production in the body and increases creatine phosphate stores. Creatine 
supplementation in athletes improved exercise  performance and muscle mass (44).  
In cancer, one study showed that eight weeks of creatine supplementation in (non-
cachectic) people with colorectal cancer did not exert any changes in quality of life or 
nutritional parameters , but did show improvements in handgrip strength and bio-electrical 
characteristics of the cell membrane, such as capacitance and phase angle, and these 
parameters were correlated with longer survival (45).  
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In a double blind placebo-controlled trial by Jatoi et al, 263 incurable malignancies with 
anorexia/cachexia symptoms were assigned creatine for 7 days (20 g/day load×5 days followed 
by 2 g/day orally) versus identical placebo. The results showed that only 3 subjects gained ≥10% 
of their baseline weight by 1 month: two creatine-treated and the other placebo-exposed 
(P = 1.00), and there were no differences between groups for appetite, quality of life, activities 
of daily living, grip strength, body composition (46). However, a 10% weight gain is not 
achievable within such a short time frame, and body composition was assessed by bio-
impedance analysis only in subgroups of 20 creatine-treated subjects and 15 placebo-exposed 
subjects, and results on body composition were not reported. This might have skewed the 
results of this study.  
With only 2 studies available with inconclusive effects of creatine, more research on 
short term metabolic effects and muscle mass and strength in people with cancer is required.  
 
Carnitine 
Carnitine is a trimethylated amino acid roughly similar in structure to choline. It is derived 
mainly from meat and dairy dietary sources, and plays a central role in the metabolism of fatty 
acids, and has antioxidant and anti-inflammatory properties. In skeletal muscle and heart 
muscles, carnitine regulates the mitochondrial ratio of free coenzyme A to acyl-coenzyme A, 
which is required for fatty acid oxidation. People with cancer, especially those underweight or 
with cachexia, are at risk of and often present with carnitine deficiency (47).  
People with cancer often have a decreased caloric intake and increased metabolic 
requirements, and numerous antineoplastic drugs can interfere with the absorption and 
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synthesis of carnitine (47). This has led to preliminary studies on L-carnitine supplementation in 
people with cancer cachexia. Overall these studies indicate improved fatigue and quality of life, 
and improvements in nutritional variables of appetite, total body weight and lean body mass.  
Studies by Kraft (48) and Gramignano (49) showed L-carnitine supplementation resulted 
in significant improvements in BMI (48), LBM and appetite (49). In a study by Mantovani L-
carnitine supplementation in combination with a progestational agent, eicosapentaenoic acid 
and thalidomide had a positive effect on LBM, fatigue and appetite. However L-carnitine 
supplementation alone did not have the same positive effect (50). 
Gramignano’s study of 12 people with advanced cancer confirmed the significant 
improvement of fatigue and quality of life  with L-carnitine supplementation (6g/day). Similarly 
Mantovani’s large phase III study demonstrated interim results of significant improvements in 
fatigue when 4g/d L-carnitine was supplemented (50). Despite this promising preliminary result, 
L-carnitine  did not impact any primary endpoints such as fatigue  or LBM and appetite in 
cancer however did impact on secondary outcomes such as performance status and 
inflammation based prognostic scores (50). 
 There is evidence that L-carnitine is able to reduce chronic inflammation and oxidative 
stress in cancer. Several animal studies have shown the anti-inflammatory effects of L-carnitine 
supplementation (51,52). Gramignano found that levels of reactive oxygen species decreased 
and glutathione peroxidase increased  with L-carnitine supplementation in people with 
advanced cancer but not significantly. Proinflammatory cytokines also did not change 
significantly (49).  
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These studies highlight that L-carnitine is an interesting potential agent in the treatment 
of cancer cachexia however the efficacy of such supplementation to improve cachexia 
symptoms requires further investigation. These studies shed light on some of the longer term 
effects in people with cancer however short term metabolic effects of L-carnitine 
supplementation is yet to be investigated in human studies. 
 
Glutamine and arginine 
Glutamine and arginine are conditionally essential amino acids, which means that the body can 
produce them, but not in sufficient amounts during stress. Glutamine is converted to citrulline 
in the gastrointestinal tract, and in the kidneys metabolised to arginine + NO (53). The 
availability of arginine depends on dietary intake and the de novo synthesis from citrulline. 
There are indications that dietary arginine and citrulline stimulate muscle protein synthesis. 
Citrulline is more effective per gram than arginine. As citrulline gets converted into arginine, 
citrulline could be effective in stimulating muscle protein synthesis (53).  
In cancer there has been a lot of interest in the effects of glutamine on gastrointestinal 
toxicity, for instance during radiation or chemotherapy. There is emerging evidence suggesting 
that supplementation of oral glutamine decreases the incidence and/or severity of 
chemotherapy-associated mucositis, diarrhea, neuropathy, veno-occlusive disease and 
cardiotoxicity. It is suggested that glutamine protects normal tissues from chemo-related injury, 
and to sensitize tumor cells to chemotherapy and radiation (54). A retrospective study by Gul et 
al looked at the effects of oral glutamine powder (10g tid) on acute radiation-induced 
esophagitis and weight loss and survival in people with non-small lung cancer (NSCLC). During a 
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median follow up of 13 months, there was a lower prevalence of severe esophagitis and less 
weight loss  in the supplemented group (55,56). These results need to be confirmed by well-
designed prospective studies.  
Arginine activates  the mTOR signalling pathway in muscle tissue and in this way 
enhances protein synthesis and possibly inhibiting proteolysis (57). In healthy humans, arginine 
administration enhanced exercise endurance and muscle force (57). Dietary supplementation of 
arginine in cancer has mostly been studied in perioperative settings as part of immunonutrition. 
There is some evidence that immunonutrition reduces the surgery-induced immune 
suppression, postoperative complications and infections, length of stay (58).  
Despite the application of glutamine and arginine in human research, there are no 
studies on acute effects of glutamine and arginine on protein metabolism in people with 
cancer.  
 
Conclusion 
Amino acids from protein are known to be the building blocks of muscle mass and are required 
to achieve muscle maintenance in people with cancer. This review summarised the existing 
metabolic studies on effects of oral administration of amino acids or their metabolites. The 
studies showed that people with cancer are able to achieve protein anabolism in response to an 
oral meal or a supplement high in protein. This occurred in people with early and more 
advanced stages of cancer, and in people with inflammatory and critical weight loss as well as in 
those with a stable weight. Mixtures high in essential amino acids were more effective than 
traditional amino acid mixtures. Branched chain amino acids have beneficial short term effects 
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on protein metabolism, but more research is needed. This also applies to other nutrients that 
have been claimed to be anabolic, such as HMB, creatine, and L-carnitine. 
The identified studies were small and differed with regard to cancer types, disease 
stages, inflammatory state, levels of involuntary weight loss and type of oral intervention. We 
advocate larger acute as well as long term metabolic studies in common types of cancer. In 
addition, more research is needed on the metabolic effects of other nutrients that are claimed 
to have positive effects on muscle buildup in people with cancer, such as vitamin D and omega-
3 polyunsaturated fatty acids from fish oil. As there could be a synergistic effect of combination 
supplements, future research should also focus on the effects of a multicomponent approach 
combining a number of effective nutrients.  
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Table 1 Amino acid kinetic studies assessing Protein Synthesis in response to oral feeding in patients with cancer 
 
Study 
Design 
Cancer Type Nutritional status / 
Systemic inflammation 
Study Design Type of Oral 
Feeding 
Results PS 
Oral amino acids 
Dillon  
2007 
ORAL 
AA 
Ovarian (stage 
IIIC) (n=6) 
 
 
- Weight loss: >10% in 
n=6 (100%) 
- BMI: 22.0 ± 3 kg/m2 
- CRP: 7.7 ± ng/mL 
- > 6 months post 
surgery 
- n=8 healthy older 
controls 
- Primed continuous 
IV of labeled PHE 
(prime: 2 µmol/kg, 
cont: 0.05 
µmol/kg/min) 
- 40 g amino 
acids (18 g EAA 
and 22 g non-
EAA) 
- Boluses (30 mL) 
every 10  
minutes for 3 h 
(total: 540 mL)  
- Amount of AA 
resembling 
meat protein 
(based on Volpi, 
ACJN 2003) 
 
- Skeletal muscle TNF-alpha, IL-6, NF-kB 
were elevated.  
- Muscle fractional synthesis rate 
increased significantly 
- Protein breakdown remained unchanged 
- PHE balance improved 
- AA were capable of stimulating muscle 
protein synthesis 
 
 
MPS 
FSR 
Engelen 
2015 
ORAL 
AA 
NSCLC, 
advanced 
(stage III and 
IV)  
(n=13) 
- Weight loss: >5% 
weight loss in 3-6 
months in n=5 (38%) 
- BMI: 26.5 ± 1.1 kg/m2 
- CRP: 9.8 ± 3.7 mg/l 
- > 4 wks after cancer 
treatment 
 
- n=11 healthy age-
matched controls 
- Randomized, 
double-blind, 
crossover design 
- Primed, constant, 
continuous IV of 
labeled PHE and TYR  
 250 ml non-
caloric soft-
drink w L-15N 
PHE with 30 g 
maltodextrin 
 E: 14 g of free 
EAA with high 
leucine levels 
(EAA/leucine) 
 C: 14 g 
balanced amino 
acid mixture 
with EAA + non-
EAA (whey 
protein) 
- Postabsorptive PS and PB comparable in 
cancer and controls 
- PS and net protein anabolism > after 
intake of EAA/leucine than C mixture (P < 
0.001) in cancer and healthy subjects 
- Significant correlation between net 
protein anabolism and dietary EAA intake 
and EAA appearance in systemic 
circulation in cancer and health.  
- Presence of muscle or recent weight loss, 
systemic inflammatory response, or 
length of survival did not influence this 
relationship.  
- High leucine levels in EAA/leucine 
mixture: no anabolic benefit. 
WB 
2 
ONS 
Barber  
2000 
ORAL NS 
Pancreatic 
(n=8) 
- Weight loss: 18.9 
(12.7 – 37.5) 
- BMI: N/A 
- CRP: N/A , IL-6: E: 7.4 
(3.5 – 32.3) vs. C: 1.8 
(1.0 – 3.0) pg/ml  
(P<0.005) 
- > 4 wks after cancer 
treatment 
- n=6 healthy 
controls 
- After 2 hours of 
feeding: 2 hours of 
IV [2H5] -PHE or 
[2H8]-PHE 
Oral nutritional 
supplement (1/12 
of energy 
requirements 
(13% protein) on 
an hourly basis 
over 4 h 
- Fasting albumin synthesis rates similar 
between E and C 
- Albumin synthesis rates rose on feeding 
by 29 and 24% in cancer and controls 
- Fasting fibrinogen synthetic rate: higher 
in cancer than in controls (3.3 vs 1.0 g/d, 
P=0.0019) 
- Acute-phase protein synthesis 
upregulated in cancer 
- Similar albumin synthesis in cancer and 
controls. Albumin synthesis and 
fibrinogen synthesis upregulated during 
feeding in both groups.  
 
Deutz  
2011 
ORAL NS 
Mixed types 
(stage II to IV) 
(n=25) 
- Weight loss: 2.9 ± 2.2  
% 
- BMI: 25.1 ± 3.3 kg/m2 
- CRP: 28.7 ± 8.2 ng/ml 
- > 4 wks after cancer 
treatment 
- E: n=13, C: n=12 
 Priming dose (2 
mmol/kg) of L-
[ring-13C6] PHE, 
followed by a 
continuous (0.07 
mmol/kg/min) 
infusion 
- Muscle biopsy 2 h 
and 5 h after start 
IV 
- E: oral 
nutritional 
supplement, 2 * 
200 mL (640 
kcal, 40 g 
protein (27%), 
24.2 g casein, 
11.9 g whey, 
4.16 g free 
leucine, 8.38 g 
fish oil (2.2 g of 
EPA and 1.1 g 
DHA), specific 
oligosaccharide
s 
- C: 2 * 200 mL 
conventional 
oral nutritional 
supplement 
(640 kcal, 24 g 
- Plasma leucine increased in E: 7.8 g, vs. 
C: 2.0 g (P<0.001) 
- Postabsorptive muscle protein FSR was 
similar in E and C 
- Absorptive MPS: 0.073 (SD: 0.023) to 
0.097 (SD: 0.033) %/h (P=0.027), C: no 
change: 0.073 (SD: 0.022), to 0.065 (SD: 
0.028) %/h, P>0.05. 
 
 
MPS 
FSR 
3 
(15%) casein 
protein)  
Van Dijk 
2015 
ORAL NS 
Pancreas 
(n=8) 
- Weight loss: >10% in 
n=7 (88%) 
- BMI: 20.0 kg/m2 
- CRP: 8.3 (IQR: 4.2–
31.3) mg/L 
- > 4 wks after cancer 
treatment 
- n=7 healthy 
controls 
- Primed continuous 
intravenous 
infusion of L-ring-
[2H5]PHE and L-3,3 
2H2]TYR for 8 h 
- sip feeds with L-
1[13C-PHE] 
- 480 ml water 
sips, 60 ml 
every 30 min 
- 480 ml sip 
feeds (oral 
nutritional 
supplement: 50 
g casein, 5.25 g 
leucine. 60 ml 
every 30 min (4 
h in total) 
 
- Baseline: PB higher in E than in C (67.1 vs. 
45.8 ųmol/kg LBM) 
- PB decreased during ingestion (45.5 in E 
vs. 33.7 ųmol/kg LBM) 
- Splanchnic extraction similar between E 
and C during feeding 
- PS higher in weight-losing E pts than in C 
at baseline 
- PS did not respond to sip feeding in E, in 
contrast with C (P=0.018): 58.4 vs. 47.9 
ųmol/kg LBM) 
- Net protein balance comparable 
between E and C 
WB 
Engelen 
2017 
ORAL NS 
Breast (stage 
II) 
(n=9) 
- Weight loss: none 
- BMI: 28.5 ± 5.1 kg/m2 
- CRP: 3 mg/L 
- > 4 wks after cancer 
treatment 
 
- n=9 healthy 
controls 
- Prior to and within 
24 h after 
mastectomy 
surgery 
- Primed, constant, 
and continuous 
infusion of labeled 
PHE and TYR 
- Oral nutritional 
supplement intake 
after 1.5 h of 
primed, continuous 
isotope infusion 
Oral nutritional 
supplement (240 
kcal, 15 g protein) 
+ 158.8 mg L-15N 
PHE 
 
 
- PS and net balance E > C (P < 0.001) 
- Major surgery resulted in an up-
regulation of post-absorptive protein 
synthesis and breakdown rates (P<0.001) 
and lower net protein catabolism 
(P<0.05) and was associated with insulin 
resistance and increased systemic 
inflammation (P<0.01).  
- Net anabolic response to the meal was 
reduced after surgery (P<0.05) but higher 
in cancer (P<0.05) indicative of a more 
preserved meal efficiency.  
- Significant positive correlation between 
net protein anabolism and AA 
appearance in systemic circulation, 
independent of the presence of non-
cachectic early stage breast cancer or 
surgery. 
WB 
Oral meals 
4 
Glass  
1983 
ORAL 
MEALS 
Colorectal 
(n=11) 
- Weight loss: n=6 
(55%) 
- BMI: N/A 
- CRP: N/A 
- No previous cancer 
treatment 
- Before and after 
tumour resection 
- Urinary secretion 
of 15N in ammonia 
and urea over a 9h 
period after an oral 
dose of [15N]-
glycine 
Identical food 
intake for 2 days 
(ad libitum on day 
preceding the 
pre-operative 
study, and 6 equal 
portions every 2 h 
during the 
experimental 
period 
 
- No significant differences in rates of 
nitrogen flux, protein synthesis and 
protein breakdown were found before 
and after tumour resection 
 
WB 
Emery 
1984 
ORAL 
MEALS 
Lung (n=4, 
kidney (n=1) 
- Weight loss: n=5 
(100%), average 10.1 
± 5.9%  
- BMI: N/A 
- CRP: N/A 
- No previous cancer 
treatment 
- n=7 healthy 
controls 
- IV Prime (1mg/kg) 
of 13C L-leucine and 
13C sodium 
bicarbonate 
(0.08mg/kg), 
constant infusion 
of carboxyl 13C 
labeled L-leucine 1 
mg/kg/h).  
Hourly meals of a 
milk based liquid 
diet (⅔ of normal 
daily intake of 
protein and 
energy over 10 
hours (0.4-0.8 g 
protein/kg/h, 4-8 
kJ/kg/h)  
- Protein synthesis in muscle was much 
lower in E than in C (0.198 ± 0.020 %/h 
vs. 0.030 ± 0.007 %/h, P=0.01) 
- No difference between E and C for whole 
body protein synthesis and breakdown 
 
MPS 
WB 
Melville  
1990 
ORAL 
MEALS 
Lung 
(n=9) 
 
- Weight loss: n=6 
(67%) 
- BMI: 22.6 ± 2.8 kg/m2 
- CRP: N/A 
- No previous cancer 
treatment 
- n=9 control 
(elective aneurysm 
surgery) 
- Primed continuous 
infusion of [13C]- 
leucine (2.3 
ųmol/kg/h+ prime 
dose of 1.9 
ųmol/kg) 
4 hourly meals 
(bread, 
margarine, 
cheese, raisins, 
milk): 1/12 of 
daily energy 
expenditure 
- Postabsorptive incorporation of leucine 
into protein: higher in E (102 ± 21 vs 86 ± 
8) p<0.05 
- Release of leucine by protein 
degradation higher in E: 126 ± 19 vs 110 
10 ųmol/kg LBM/h p<0.01), no 
differences for leucine oxidation 
- During feeding, incorporation of leucine 
into protein  (106 ± 20 versus 89 ± 7 
ųmol/kg LBM/h, P <0.05) and release (59 
± 12 venus 42 ± 14 ųmol/kg LBM/h, P < 
0.02) remained higher in E than in C. 
Leucine oxidation (43 ± 15 versus 43 ± 12 
WB 
5 
ųmol/kg LBM/h) and leucine balance 
(+48 ±10 versus +47 ± 12 ųmol/kg 
LBM/h) were the same. 
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Table 2 Basic chemical properties and mechanism of action of nutrients with potential beneficial effects on muscle protein synthesis in cancer 
 
Agent Basic chemical properties 
Branched-chain amino acids 
(BCAA) 
● Essential amino acids with a similar lateral radical chain (leucine, isoleucine, valine) 
● Transaminated in skeletal muscle during exercise and assisting with muscle recovery 
● Activate the mTOR pathway when glutamine is lacking (e.g. in cancer) 
ß-hydroxy-ß-methylbutyrate 
(HMB) 
● α-amino acid 
● Used in biosynthesis of proteins 
● Conditionally essential in states where tissue is being built or repaired (illness, wound healing) 
● Synthesised in the body from glutamate and ammonia 
Creatine ● Organic compound 
● Facilitates recycling of ATP 
● Synthesis in liver and kidneys from glycine and arginine 
● Tissues with high energy demands (brain and skeletal muscle) 
● Creatine kinase in brain/muscles: re-synthesizes ATP from ADP to meet increased energy demands 
Carnitine ● Trimethylated amino acid (roughly similar in structure to choline) 
● Plays a central role in the metabolism of fatty acids 
● Antioxidant and anti-inflammatory properties 
● Cancer increases the risk of carnitine deficiency 
Arginine ● Conditionally essential amino acid (the body cannot produce in sufficient amounts during stress.  
● Availability depends on dietary intake and the de novo synthesis from citrulline 
● Dietary arginine and citrulline stimulate muscle protein synthesis (citrulline is more effective per gram 
than arginine) 
Glutamine ● Conditionally essential amino acid 
● Glutamine is converted to citrulline in the gut, and in the kidneys metabolised to arginine + NO 
● Protects normal tissues from chemo-related injury, and sensitizes tumor cells to chemotherapy and 
radiation 
ADP: adenosine diiphosphate, ATP: adenosine triphosphate, mTOR: mammalian target of rapamycin, NO: nitric oxide 
 
 
